P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
Key claim: A phase 3 double-blind trial is testing bi-weekly ropeginterferon alfa-2b (P1101) versus placebo (2:1) in adults with early or low to intermediate-1 risk primary myelofibrosis.
Abstract
This is a phase 3 double-blind clinical trial arm to test Ropeginterferon alfa-2b (P1101) in adult patients with Primary Myelofibrosis (PMF) at early stage or low to medium risk.
Participants will receive the study drug/placebo bi-weekly and have an assessment visit every 4 weeks. The ratio of study drug to placebo group is 2:1.
Why this matters
Early and low-risk PMF have historically been managed with observation or symptom-directed therapy borrowed from ET, with no approved disease-modifying agent and few late-stage trials targeting the lower-risk end of the fibrotic spectrum. A phase 3 placebo-controlled evaluation of ropeginterferon alfa-2b in this population could establish whether interferon’s PV/ET disease-modification signal extends earlier in the PMF natural history, potentially reshaping when disease-directed therapy begins in the highest-mortality MPN subtype.